Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 May 25;153(8):3747–3757. doi: 10.1210/en.2012-1138

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2012 by The Endocrine Society

PMC Copyright notice

Fig. 7. — Improvement of neurological outcomes by allopregnanolone at 48 h after MCAO does not involve PR. A, Reduction in infarct volume by allopregnanolone. Two-way ANOVA revealed a significant effect of allopregnanolone treatment (P < 0.01) but no influence of PR genotype for total, cortical, and subcortical infarct volumes. ***, P < 0.001; **, P < 0.01; *, P < 0.05 as compared with the corresponding control group. B, Infarct areas on successive brain sections of PR^+/+ and PR^−/− mice. ***, P < 0.001; **, P < 0.01; *, P < 0.05 as compared with the corresponding sections of allopregnanolone-treated mice. C, Reduction of edema by allopregnanolone (means ± sem) in both PR^+/+ and PR^−/− mice. Two-way ANOVA (PR genotype × treatment) showed a significant effect of treatment (P < 0.001) but no effect of PR genotype. **, P < 0.01; *, P < 0.05 as compared with corresponding control group by Newman-Keuls tests. D, The time mice remained on a rotarod. ***, P < 0.001, *, P < 0.05 compared with preischemia performance; ##, P < 0.01 as indicated. Data represent means ± sem; n = 6–8 for vehicle- and allopregnanolone-treated mice.